HDAC6 and Alzheimer disease: Together, we propose that increased acetylation of Prx1 by HDAC6 inhibition leads to recovery of Aβ-induced pathology such as elevation of ROS and Ca2+ and impaired axonal transport, making HDAC6 a possible therapeutic target for AD.